Head-to-head dispatch
Empower Pharmacy vs Sunlight
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Major 503B compounding pharmacy that supplies compounded GLP-1 medications to telehealth providers.
Marked down on: Pricing not publicly disclosed
FDAWarning letter issued to Empower Clinic Services, LLC dba Empower Pharmacy in April 2025. See the FDA warning-letter database.
Desk Score
A LegitScript-certified compounded GLP-1 telehealth brand with flat, openly published pricing — semaglutide from $88/mo, tirzepatide from $157/mo — plus a separate peptide-therapy program (NAD+, and per the live site, sermorelin) under its own intake.
Starts at $88/mo (compounded, injection) sema · Starts at $157/mo (compounded, injection) tirz · Verified August 4, 2026
Marked down on: Injectable only for GLP-1 — no oral tablet route on semaglutide or tirzepatide, despite a generic "Injections and oral options available" line in one landing page's hero that matches nothing else on the site
Sunlight takes this head-to-head with the higher Desk Score, 84/100 (B) against 57/100 (C) for Empower Pharmacy. Empower Pharmacy still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Empower Pharmacy
57/100
C
Sunlight
84/100
B
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Empower Pharmacy | Sunlight |
|---|---|---|
| Semaglutide | Not listed on Empower Pharmacy's site (checked July 20, 2026) | Starts at $88/mo (compounded, injection) |
| Tirzepatide | Not listed on Empower Pharmacy's site (checked July 20, 2026) | Starts at $157/mo (compounded, injection) |
| Coverage | All 50 states | All 50 states (varies by provider licensure) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Mainstream telehealth GLP-1 access. | Patients who want the lowest published entry price in the ranking and are comfortable with an injection-only compounded program, and don't need an oral or brand-name route. |
| Desk Score | 57/100C | 84/100B |
The verdict
Desk pick — SunlightSunlight takes this head-to-head with the higher Desk Score, 84/100 (B) against 57/100 (C) for Empower Pharmacy. Empower Pharmacy still holds its ground where its strengths line up with yours.
Choose Empower Pharmacy if…
Mainstream telehealth GLP-1 access.
All 50 states
FDAWarning letter issued to Empower Clinic Services, LLC dba Empower Pharmacy in April 2025. See the FDA warning-letter database.
Choose Sunlight if…
Patients who want the lowest published entry price in the ranking and are comfortable with an injection-only compounded program, and don't need an oral or brand-name route.
Starts at $88/mo (compounded, injection) sema · Starts at $157/mo (compounded, injection) tirz · All 50 states (varies by provider licensure)
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Empower Pharmacy · Sunlight.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: one price at every dose, both molecules, all 50 states — but the $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- Empower Pharmacy vs CoreAge Rx
- Sunlight vs Vaylen
- Empower Pharmacy vs Strut Health
- Sunlight vs Ondra Health
- Empower Pharmacy vs Invigor Medical
- Sunlight vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.